作者
Sandra A Springer, Angela Di Paola, Marwan M Azar, Russell Barbour, Breanne E Biondi, Maureen Desabrais, Thomas Lincoln, Daniel J Skiest, Frederick L Altice
发表日期
2018/5/1
期刊
JAIDS Journal of Acquired Immune Deficiency Syndromes
卷号
78
期号
1
页码范围
43-53
出版商
LWW
简介
Objective:
To determine whether extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use disorder (OUD) transitioning to the community.
Design:
A 4-site, prospective randomized double-blind, placebo-controlled trial was conducted among prison and jail inmates with HIV and OUD transitioning to the community from September 2010 through March 2016.
Methods:
Eligible participants (N= 93) were randomized 2: 1 to receive 6 monthly injections of XR-NTX (n= 66) or placebo (n= 27) starting at release and observed for 6 months. The primary outcome was the proportion that maintained or improved VS (< 50 copies/mL) from baseline to 6 months.
Results:
Participants allocated to XR-NTX significantly improved to VS (< 50 copies/mL) from baseline (37.9%) to 6 months (60.6%)(P= 0.002), whereas the placebo group did not (55.6 …
学术搜索中的文章
SA Springer, A Di Paola, MM Azar, R Barbour… - JAIDS Journal of Acquired Immune Deficiency …, 2018
SA Springer, A Di Paola, R Barbour, MM Azar, FL Altice - Journal of acquired immune deficiency syndromes …, 2018